<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123098">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500057</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB Protocol# 20111638</org_study_id>
    <nct_id>NCT01500057</nct_id>
  </id_info>
  <brief_title>Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia</brief_title>
  <official_title>An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooklyn Urology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Richard Wolf Medical Instruments Corporation (RWMIC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooklyn Urology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus
      BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic
      Hyperplasia (BPH). The study consists of a screening phase, treatment, followed by follow-up
      visits at 1 week, 4 weeks, 3 months, 6 months, and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 10, 2016</completion_date>
  <primary_completion_date type="Actual">October 10, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUA Symptom score</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>uroflow and post void residual</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Greenlight XPS Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Greenlight XPS Laser of the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BiVAP Saline Vaporization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BiVAP Saline Vaporization of the prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Greenlight XPS Laser</intervention_name>
    <description>Treatment of BPH with Greenlight XPS laser</description>
    <arm_group_label>Greenlight XPS Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiVAP Saline Vaporization of the prostate</intervention_name>
    <description>treatment of BPH with BiVAP Saline Vaporization</description>
    <arm_group_label>BiVAP Saline Vaporization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male over the age of 18 years

          -  present with symptomatic/ obstructive symptoms secondary to PBH requiring surgical
             intervention

          -  subjects must read, understand and sign the Informed Consent

          -  AUA ≥ 15

          -  Qmax &lt; 15mL/sec

          -  Stopped BPH medication. Alpha blockers 15 days 5-α-reductase 3 months

          -  Prostate volume ≥ 30g

        Exclusion Criteria:

          -  PVR &gt; 300ml

          -  Current urine retention

          -  Previous surgical or invasive treatments (TURP, TUMT, TUNA)

          -  PSA ≥ 4 (must have negative biopsy within last 12 months)

          -  Neurogenic bladder

          -  Obstruction due to urethral stricture

          -  Any disorder or condition of the subject that the investigator believes will counter
             indicate their inclusion in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>December 16, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooklyn Urology Research Group</investigator_affiliation>
    <investigator_full_name>Ivan Grunberger, MD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>enlarged prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
